Q3 2022 Excelsior Newsletter
Excelsior’s Opinion on So-Called “Vision Enhancement Products” by Robert Kordella, RPh, MBA, Chief Clinical Officer Three products have come to market recently that are being
Excelsior’s Opinion on So-Called “Vision Enhancement Products” by Robert Kordella, RPh, MBA, Chief Clinical Officer Three products have come to market recently that are being
Humira Savings on the Horizon? by Robert Kordella, RPh, MBA, Chief Clinical Officer In
Some Good News Due to Upcoming Generics by Robert Kordella, RPh, MBA, Chief Clinical
Medication Adherence: Is it a Waste of Money? by Shavsha Davis, Assistant Vice President
Diabetes: What’s driving non-specialty trend? by Matt Jarvis, PharmD, Vice President, Pharmacy Practice Leader
Dispense As Written Prescription Instructions and Their Impact on Plan Sponsors and Participants by
Common Sense Management of Narcolepsy and Cataplexy by Bob Kordella, R.Ph., MBA, Chief Clinical
November 30, 2020:Where We Are Today And When Will New Vaccines Be Approved? by
COVID-19 Vaccine Update by Bob Kordella, R.Ph., MBA, Chief Clinical Officer As several COVID-19
The Rebate Bubble by Jonalan Smith, PharmD, FASCP, Senior Vice President Everyone knows the
© Copyright 2019 Excelsior Solutions • Privacy Policy • All Rights Reserved